Illumina (NASDAQ:ILMN) had its price objective lowered by Deutsche Bank from $290.00 to $280.00 in a research note released on Friday morning, BenzingaRatingsTable reports. The brokerage currently has a hold rating on the life sciences company’s stock.

A number of other equities analysts also recently issued reports on the company. Canaccord Genuity reissued a buy rating and set a $360.00 price target (up previously from $350.00) on shares of Illumina in a research report on Monday, June 10th. OTR Global downgraded Illumina to a positive rating in a research report on Tuesday, April 2nd. BidaskClub raised Zumiez from a sell rating to a hold rating in a research report on Saturday, June 22nd. Bank of America set a $80.00 price target on Colgate-Palmolive and gave the stock a buy rating in a research report on Friday. Finally, Wolfe Research initiated coverage on Waters in a research report on Thursday, May 30th. They set an underperform rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $341.15.

ILMN opened at $305.05 on Friday. Illumina has a 12-month low of $268.62 and a 12-month high of $380.76. The company has a quick ratio of 3.33, a current ratio of 3.66 and a debt-to-equity ratio of 0.27. The stock’s fifty day moving average price is $344.09. The company has a market cap of $44.84 billion, a P/E ratio of 53.33, a price-to-earnings-growth ratio of 2.12 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.26. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The business had revenue of $846.00 million for the quarter, compared to the consensus estimate of $838.70 million. During the same quarter in the prior year, the company earned $1.45 EPS. The business’s revenue was up 8.2% compared to the same quarter last year. On average, equities analysts forecast that Illumina will post 6.68 EPS for the current fiscal year.

In related news, SVP Omead Ostadan sold 1,260 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $315.32, for a total transaction of $397,303.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Charles Dadswell sold 124 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $311.77, for a total value of $38,659.48. Following the sale, the senior vice president now directly owns 8,086 shares in the company, valued at approximately $2,520,972.22. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 59,291 shares of company stock worth $19,459,234. 0.38% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jennison Associates LLC boosted its holdings in Illumina by 3.7% in the first quarter. Jennison Associates LLC now owns 5,679,678 shares of the life sciences company’s stock worth $1,764,619,000 after acquiring an additional 200,114 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Illumina by 10.1% in the fourth quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock worth $555,173,000 after acquiring an additional 170,046 shares in the last quarter. Norges Bank acquired a new stake in Illumina in the fourth quarter worth about $514,627,000. Northern Trust Corp boosted its holdings in Illumina by 0.9% in the first quarter. Northern Trust Corp now owns 1,660,761 shares of the life sciences company’s stock worth $515,981,000 after acquiring an additional 14,669 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in Illumina by 107.1% in the first quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock worth $253,484,000 after acquiring an additional 421,953 shares in the last quarter. 89.81% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Recommended Story: Do You Need a Fiduciary?

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.